



Universiteit
Leiden
The Netherlands

Advances in clinical development for vaccines and therapeutics against respiratory virus infections

J.L. van der Plas

Citation

Advances in clinical development for vaccines and therapeutics against respiratory virus infections. (2023, September 26). *Advances in clinical development for vaccines and therapeutics against respiratory virus infections.* Retrieved from <https://hdl.handle.net/1887/3642223>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3642223>

Note: To cite this publication please use the final published version (if applicable).

ADVANCES IN CLINICAL DEVELOPMENT FOR VACCINES AND THERAPEUTICS AGAINST RESPIRATORY VIRUS INFECTIONS

Proefschrift

ter verkrijging van
de graad van doctor aan de Universiteit Leiden,
op gezag van rector magnificus prof.dr.ir. H. Bijl,
volgens besluit van het college voor promoties
te verdedigen op dinsdag 26 september 2023

klokke 11.15 uur

door

Johan Leendert van der Plas
geboren te Katwijk aan Zee

in 1991

© J.L. van der Plas, 2023

DESIGN: Caroline de Lint, Den Haag (caro@delint.nl)

IMAGE: Electron microscopy image framed in blue

Publication of this thesis was financially supported by the foundation
Centre for Human Drug Research in Leiden, the Netherlands.

PROMOTOR

Prof. dr. J. Burggraaf

CO-PROMOTOR

Dr. I.M.C. de Visser-Kamerling

LEDEN PROMOTIECOMMISSIE

Prof. dr. L.G. Visser

Prof. dr. W.J.M. Spaan

Prof. dr. B.C.P. Koch (*Erasmus Medisch Centrum, Rotterdam*)

Prof. dr. M. van Egmond (*Amsterdam Universitair Medisch Centrum, Amsterdam*)

8	CHAPTER 1 Introduction
SECTION 1 RESPIRATORY SYNCYTIAL VIRUS	
24	CHAPTER 2 Prevalent levels of rsv serum neutralizing antibodies in healthy adults outside the rsv-season
36	CHAPTER 3 First-in-human administration of a live-attenuated rsv vaccine lacking the G-protein assessing safety, tolerability, shedding and immunogenicity: a randomized controlled trial
SECTION 2 INFLUENZA VIRUS	
60	CHAPTER 4 Safety, reactogenicity and immunogenicity of an intranasal seasonal influenza vaccine adjuvanted with gram-positive matrix (GEM) particles (FluGEM®): a randomized, double-blind, controlled, ascending dose study in healthy adults and elderly
SECTION 3 SARS-COV-2 AND CLINICAL DEVELOPMENT DURING PANDEMICS	
86	CHAPTER 5 Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate covid-19 – a phase 2a, open-label, single dose escalation study
106	CHAPTER 6 Immunosuppression by hydroxychloroquine: mechanistic proof in in vitro experiments but limited systemic activity in a randomized placebo-controlled clinical pharmacology study
128	CHAPTER 7 Accelerating vaccine trial conduct in a pandemic with a hot spot-based inclusion strategy using trial and epidemic simulation
146	CHAPTER 8 How to expedite early-phase sars-cov-2 vaccine trials in pandemic setting-A practical perspective
154	CHAPTER 9 Discussion and future perspectives
168	Nederlandse samenvatting
181	Curriculum Vitae
182	List of publications